Biomarin Pharmaceutical (BMRN) Net Margin (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Net Margin came in at 13.77% in Q1 2026, down 1115.0% YoY from 1.36% in Q1 2025, and up 358.63% on a QoQ basis from 5.33% in Q4 2025.
Biomarin Pharmaceutical (BMRN) Net Margin (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Net Margin data on file, last reported at 13.77% in Q1 2026.
- Quarterly Net Margin fell 1115.0% year-over-year to 13.77% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8.29% (down 947.0% YoY) and the FY2025 annual result came in at 10.83%, down 413.0% from the prior year.
- Net Margin advanced to 13.77% in Q1 2026, from 5.33% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 29.14% in Q2 2025 to a low of 5.33% in Q4 2025.
- A 5-year average of 10.2% and a median of 9.41% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin soared 1968 bps — and 2025, when it tumbled 2204 bps.
- Tracing BMRN's Net Margin over 5 years: stood at 0.05% in 2022, then soared by 6907 bps to 3.15% in 2023, then soared by 430 bps to 16.72% in 2024, then slumped by 132 bps to 5.33% in 2025, then soared by 359 bps to 13.77% in 2026.
- The last three Net Margin figures came in at 13.77% (Q1 2026), 5.33% (Q4 2025), and 3.96% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | 4.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.52% |
| Mar 31, 2026 | 13.77% |
| Dec 31, 2025 | -5.33% |
| Sep 30, 2025 | -3.96% |
| Jun 30, 2025 | 29.14% |
| Mar 31, 2025 | 24.92% |
| Dec 31, 2024 | 16.72% |
| Sep 30, 2024 | 14.22% |
| Jun 30, 2024 | 15.05% |
| Mar 31, 2024 | 13.66% |
| Dec 31, 2023 | 3.15% |
| Sep 30, 2023 | 6.95% |
| Jun 30, 2023 | 9.41% |
| Mar 31, 2023 | 8.53% |
| Dec 31, 2022 | -0.05% |
| Sep 30, 2022 | -1.32% |
| Jun 30, 2022 | 5.18% |
| Mar 31, 2022 | 23.26% |
| Dec 31, 2021 | -12.87% |
| Sep 30, 2021 | -8.93% |